Atsushi Komaru

Dr. Atsushi Komaru

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Urology
Verified
Journal Article
Closed access
NKNaoto Kamiya
Naoto Kamiya
HSHiroyoshi Suzuki
Hiroyoshi Suzuki
MYMasashi Yano
Masashi Yano
TETakumi Endo
Takumi Endo
MTMakoto Takano
Makoto Takano
TITomohiko Ichikawa
Tomohiko Ichikawa

1 October 2009 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AKAtsushi Komaru
Atsushi Komaru
YUYasuji Ueda
Yasuji Ueda
AFAki Furuya
Aki Furuya
STSakura Tanaka
Sakura Tanaka
KYKumi Yoshida
Kumi Yoshida
YYYoshikazu Yonemitsu
Yoshikazu Yonemitsu
We recently demonstrated efficient antitumor immunity against murine tumors using dendritic cells (DCs) activated by recombinant Sendai viruses (rSeVs), and proposed a new concept, “immunostimulatory virotherapy,” for cancer immunotherapy. However, there has been little information on the efficacy of this method in preventing metastatic diseases. In this study, we investigated the efficacy of vaccinating DCs activated by fusion gene-deleted nontransmissible rSeV (rSeV/dF) using a murine model of lung metastasis. Bolus and i.v. administration of DCs harboring rSeV/dF-expressing GFP without pulsation of tumor Ag (DC-rSeV/dF-GFP) 2 days before tumor inoculation showed efficient prevention against lung metastasis of c1300 neuroblastoma, but not of RM-9 prostatic cancer. We found that the timing of DC therapy was critical for the inhibition of pulmonary metastasis of RM-9, and that the optimal effect of DCs was seen 28 days before tumor inoculation. Interestingly, the antimetastatic effect was sustained for over 3 mo, even when administered DCs were already cleared from the lung and organs related to the immune system. Although NK cell activity had already declined to baseline at the time of tumor inoculation, Ab-mediated depletion studies revealed that CD4+ cells as well as the presence of, but not the activation of, NK cells were crucial to the prevention of lung metastasis. These results are the first demonstration of efficient inhibition of lung metastasis via bolus administration of virally activated DCs that was sustained and NK/CD4+ cell-dependent, and may suggest a potentially new mechanism of DC-based immunotherapy for advanced malignancies.

27 November 2008 in Gene Therapy
Verified
Journal Article
Closed access
PDF file
HKH Kinoh
H Kinoh
MIM Inoue
M Inoue
AKAtsushi Komaru
Atsushi Komaru
YUY Ueda
Y Ueda
MHM Hasegawa
M Hasegawa
YYY Yonemitsu
Y Yonemitsu

6 November 2008 in Gene Therapy
Verified
Journal Article
Closed access
PDF file
KTK Tatsuta
K Tatsuta
STS Tanaka
S Tanaka
TTT Tajiri
T Tajiri
SSS Shibata
S Shibata
AKAtsushi Komaru
Atsushi Komaru
YYY Yonemitsu
Y Yonemitsu

28 April 2015 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TNTakeshi Namekawa
Takeshi Namekawa
SFSatoshi Fukasawa
Satoshi Fukasawa
AKAtsushi Komaru
Atsushi Komaru
MKMasayuki Kobayashi
Masayuki Kobayashi
YIYusuke Imamura
Yusuke Imamura
TUTakeshi Ueda
Takeshi Ueda

11 December 2017 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SMShuichi Morizane
Shuichi Morizane
MHMasashi Honda
Masashi Honda
SFSatoshi Fukasawa
Satoshi Fukasawa
AKAtsushi Komaru
Atsushi Komaru
JIJunichi Inokuchi
Junichi Inokuchi
ATAtsushi Takenaka
Atsushi Takenaka